Epoprostenol (Prostacyclin) and Pulmonary Hypertension
Authors: Alfred P. Fishman
Journal: Annals of Internal Medicine (2000)

Editorials21 March 2000Epoprostenol (Prostacyclin) and Pulmonary HypertensionAlfred P. Fishman, MDAlfred P. Fishman, MDUniversity of Pennsylvania School of Medicine; Philadelphia, PA 19104 (Fishman)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-6-200003210-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Pulmonary hypertension is a prevalent disorder, and the list of its causes is long and varied. Included in the list, which is densely populated by so-called secondary types of pulmonary hypertension, is the category of unexplained (primary) pulmonary hypertension, presumably the final common pathway for multiple unidentified causes. For those concerned with the pathogenesis of the more common and diverse pulmonary hypertensive disorders that make up the category of secondary pulmonary hypertension, interest in primary pulmonary hypertension is high because it represents a model of "pure" intrinsic pulmonary vascular disease, uncomplicated by concomitant disease of the heart or lungs. Those ...References1. Wagenvoort CA, Wagenvoort N. Pathology of Pulmonary Hypertension. New York: John Wiley; 1977. Google Scholar2. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis. 1986;134:342-6. MedlineGoogle Scholar3. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 1987;76:135-41. CrossrefMedlineGoogle Scholar4. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99:1197-208. CrossrefMedlineGoogle Scholar5. Higenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, et al . Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J. 1993;70:336-70. CrossrefGoogle Scholar6. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984;1:1046-7. CrossrefMedlineGoogle Scholar7. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-302. CrossrefMedlineGoogle Scholar9. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al . Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425-34. LinkGoogle Scholar10. Menon N, McAlpine L, Peacock AJ, Madhok R. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. Arthritis Rheum. 1998;41:466-9. CrossrefMedlineGoogle Scholar11. de la Mata J, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum. 1994;37:1528-33. CrossrefMedlineGoogle Scholar12. Humbert M, Sanchez O, Fartoukh M, Jagot JL, Sitbon O, Simonneau G. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin). Chest. 1998;114:80S-82S. CrossrefMedlineGoogle Scholar13. Wigley FM, Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, et al . Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a mulitcenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998;41:670-7. CrossrefMedlineGoogle Scholar14. Palmer SM, Robinson LJ, Wang A, Gossage JF, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest. 1998;113:237-40. CrossrefMedlineGoogle Scholar15. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Höper MM, et al . Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. Ann Intern Med. 2000;132:451-9. LinkGoogle Scholar16. Mikhail G, Gibbs J, Richardson G, Wright G, Khagani A, Banner N, et al . An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J. 1997;18:1499-504. CrossrefMedlineGoogle Scholar17. Rozensweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;14:1858-65. CrossrefGoogle Scholar18. Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Fedullo PF, et al . Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest. 1996;109:1545-9. CrossrefMedlineGoogle Scholar19. Warren JB, Higenbottam T. Caution with use of inhaled nitric oxide. Lancet. 1996;348:629-30. CrossrefMedlineGoogle Scholar20. Fishman AP, Fishman MC, Freeman BA, Gimbrone MA, Rabinovitch M, Robinson D, et al . Mechanisms of proliferative and obliterative vascular diseases. Insights from the pulmonary and systemic circulations. NHLBI Workshop summary. Am J Respir Crit Care Med. 1998;158:670-4. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Alfred P. Fishman, MDAffiliations: University of Pennsylvania School of Medicine; Philadelphia, PA 19104 (Fishman)Corresponding Author: Alfred P. Fishman, MD, University of Pennsylvania School of Medicine, 1320 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoContinuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease David B. Badesch , Victor F. Tapson , Michael D. McGoon , Bruce H. Brundage , Lewis J. Rubin , Fredrick M. Wigley , Stuart Rich , Robyn J. Barst , Pamela S. Barrett , Kenneth M. Kral , Maria M. Jöbsis , James E. Loyd , Srinivas Murali , Adaani Frost , Reda Girgis , Robert C. Bourge , David D. Ralph , C. Gregory Elliott , Nicholas S. Hill , David Langleben , Robert J. Schilz , Vallerie V. McLaughlin , Ivan M. Robbins , Bertron M. Groves , Shelley Shapiro , Thomas A. Medsger Jr. , Sean P. Gaine , Evelyn Horn , James C. Decker , and Katharine Knobil Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial Horst Olschewski , H. Ardeschir Ghofrani , Thomas Schmehl , Jörg Winkler , Heinrike Wilkens , Marius M. Höper , Jürgen Behr , Franz-Xaver Kleber , and Werner Seeger , for the German PPH Study Group*Epoprostenol for Pulmonary Hypertension in Scleroderma Elizabeth S. Klings and Harrison W. Farber Metrics Cited byIntravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertensionCurrent treatment options in children with pulmonary arterial hypertension and experiences with oral bosentanHepatitis C Virus and the LungTreprostinil for the treatment of severe digital necrosis in systemic sclerosisNitric oxide and pulmonary arterial pressures in pulmonary hypertensionTransition From Epoprostenol and Treprostinil to the Oral Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary HypertensionBeraprost therapy for pulmonary arterial hypertensionPrimary Pulmonary Hypertension and Cor PulmonaleTransitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial HypertensionContinuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial HypertensionFlolan Infusion Interruption: A Lethal Complication during Venous AccessEpoprostenol for Pulmonary Hypertension in SclerodermaElizabeth S. Klings, MD and Harrison W. Farber, MDLong-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue 21 March 2000Volume 132, Issue 6Page: 500-502KeywordsHemodynamicsNitric oxideProstacyclinPulmonary diseasesPulmonary hypertensionPulmonary vascular diseasesSclerodermaVasoconstrictionVasodilationVasodilators ePublished: 15 August 2000 Issue Published: 21 March 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...